|
Wednesday, 01 September 2010 03:55 |
|
BTG will pay Nycomed up to $16.6 million as part of an agreement designed to streamline transfer of the latter’s exclusive U.S. distribution rights to the rattlesnake antivenom CroFab™ and the digoxin-overdose antidote DigiFab™ back to BTG. Nycomed’s contractual rights to the drugs are due to end on September 30, although under terms of this contract the company has rights to sell remaining inventories for up to a further six months.
|
|
Read more...
|
|
Wednesday, 01 September 2010 03:50 |
 Intendis, Bayer HealthCare’s dermatology business, obtained rights to Kythera Biopharmaceuticals’ lead product candidate, ATX-101, outside the U.S. and Canada for $43 million. ATX-101 is currently in clinical development for the reduction of localized fat under the chin. Kythera will be eligible to receive up to $330 million if certain development, manufacturing, and commercialization milestones are met. Additionally, Kythera will receive tiered double-digit royalties based on net sales in Intendis’ territories.
|
|
Read more...
|
|
Monday, 30 August 2010 05:59 |
|
Purdue University researchers have developed a technology that has the potential to more quickly identify food-borne pathogens, aiding U.S. homeland security officials in responding to a bioterrorist attack or other emergencies.
|
|
Read more...
|
|
Monday, 30 August 2010 05:52 |
|
Nurse-Family Partnership®, a leading non-profit organization addressing the needs of low income, first-time parents and their children, has received a $210,000 grant from the WellPoint Foundation. The WellPoint Foundation, a private, non-profit organization wholly funded by WellPoint, Inc., promotes WellPoint's inherent commitment to enhance the health and well-being of individuals and families in communities that WellPoint's affiliate health plans serve. The grant will be used to help augment Nurse-Family Partnership (NFP) nurse home visitors' ongoing educational and monitoring efforts to reduce the rate of low birth-weight newborns among women enrolled in the NFP program.
|
|
Read more...
|
|
Friday, 27 August 2010 19:02 |
|
Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Hubei Tianyuan Chemical Co., Ltd. of Yangxin Nacheng Chemical Industry Zone, located in Hubei Province, China. This expected acquisition is the third of several planned acquisitions targeted at a share price in excess of US $1.50 for Biomagnetics Diagnostics’ common shares. Biomagnetics plans to rapidly transition the trading of its shares to the OTCBB.
|
|
Read more...
|
|
Friday, 27 August 2010 18:58 |
|
University of Rochester Medical Center (URMC) has obtained a $15 million five-year grant from the NIAID to investigate ImmuneRegen BioSciences’ Homspera in various radiation-induced injury settings. Research will expand on studies already being performed at URMC evaluating the efficacy of this adult stem cell product in mitigating lung injury induced by radiation exposure.
|
|
Read more...
|
|
Wednesday, 25 August 2010 04:53 |
|
Governor Martin O'Malley announced today that State grants are available in Fiscal Year 2011 through the Maryland Biotechnology Center to assist in commercializing promising research, encouraging bio companies to collaborate with academic institutions and expanding biotechnology resources. The Governor also announced that seven Maryland bio companies and universities received $1.3 million in FY 2010 grants, which was the first year of funding.
|
|
Read more...
|
|
Wednesday, 25 August 2010 04:05 |
|
The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) announced the latest grant recipients of its New Therapy Grants Program, a unique joint venture of the non-profit epilepsy organizations, to advance promising epilepsy research in clinical development. The grant awards, totaling approximately $200,000 in funding, will support an experimental gene therapy that directly targets epileptogenic brain tissue, as well as an electrode system that has the potential to improve the efficacy of surgical therapies for certain epilepsy syndromes.
|
|
Read more...
|
|
Monday, 23 August 2010 05:17 |
|
A team led by the Georgia Institute of Technology has received a $10 million "Expeditions in Computing" award from the National Science Foundation (NSF) to develop novel computing techniques for measuring and analyzing the behavior of children.
|
|
Read more...
|
|
Monday, 23 August 2010 04:24 |
 AIDS Healthcare Foundation (AHF), the largest global AIDS organization, responded to today's announcement by the Obama Administration that it will allocate $30 million in funding to address the national AIDS Drug Assistance Program crisis that has left 3,000 Americans on waiting lists to receive lifesaving AIDS medications by saying "Thank you, but it is not nearly enough."
|
|
Read more...
|
|
|
Wednesday, 01 September 2010 03:52 |
 Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates, announced that it has entered into a loan and security agreement with MidCap Financial and Silicon Valley Bank, providing access to up to $15 million of capital to the company.
|
|
Read more...
|
|
Wednesday, 01 September 2010 03:41 |
|
Emergent BioSolutions has been awarded a potentially $28.7 million NIAID contract to progress clinical development of a third-generation anthrax vaccine candidate that combines its FDA-approved BioThrax® vaccine with the immunostimulatory compound VaxImmune™ (CPG 7909). Emergent says the new contract means total U.S. government funding for development of the vaccine could now reach over $58 million. Phase II trials are anticipated to start in the first quarter of 2012.
|
|
Read more...
|
User Rating :  / 1
|
Monday, 30 August 2010 05:55 |
|
The University of Maryland has received a $1.9 million grant from the National Science Foundation to acquire a superconducting 800 MHz Nuclear Magnetic Resonance (NMR) spectrometer that will help scientists and engineers to solve complex problems in biology and medicine. The instrument will be the highest field NMR spectrometer to be located on the College Park campus and will enable scientists to investigate the three-dimensional structure of biological molecules and study their interactions with a degree of resolution and sensitivity not previously possible.
|
|
Read more...
|
|
Monday, 30 August 2010 04:55 |
|
Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease.
|
|
Read more...
|
|
Friday, 27 August 2010 19:01 |
|
Aileron Therapeutics and Roche announced today that they have entered into a collaboration to discover, develop, and commercialize a new class of drugs called stapled peptide therapeutics. Roche will provide Aileron guaranteed funding of at least $25 million in technology access fees and R&D support.
|
|
Read more...
|
|
Friday, 27 August 2010 18:57 |
|
Alexza Pharmaceuticals licensed its Staccato nicotine technology to Cypress Bioscience for $5 million. The Staccato technology will be used to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation but avoiding the harmful side effects associated with cigarettes.
|
|
Read more...
|
|
Wednesday, 25 August 2010 04:26 |
 Merck announced the Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional $60 million to support Botswana's African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada. A unique program developed with and led by the Government of Botswana, ACHAP is one of sub-Saharan Africa's oldest, most successful public-private partnerships. With today's pledge, the Merck Foundation and the Gates Foundation's total cash contributions now amount to $166.5 million. Merck will also continue the donation of its HIV medicines.
|
|
Read more...
|
|
Wednesday, 25 August 2010 03:41 |
|
to-BBB, the Dutch brain drug delivery company, announces that the Food and Drug Administration (FDA) has granted orphan drug designation for to-BBB’s brain cancer lead product 2B3-101.
|
|
Read more...
|
|
Monday, 23 August 2010 05:14 |
|
"Acknowledging that the development of medical countermeasures against bioterrorism threats and pandemic flu is lagging, [U.S.] federal authorities Thursday announced a $1.9 billion makeover of the system for identifying and manufacturing drugs and vaccines for public-health emergencies," Tribune Company/Seattle Times reports. "The overhaul includes manufacturing refinements aimed at shaving weeks off the time it takes to produce pandemic flu vaccine and a series of steps aimed at more quickly detecting promising scientific discoveries and getting them to market," the news service writes (Zajac, 8/19).
|
|
Read more...
|
|
Friday, 20 August 2010 23:05 |
|
Achillion Pharmaceuticals expects to net $50 million through a $50.1 million private placement of stock and warrants with a group of institutional and accredited investors. The new funds will be used to progress the firm’s pipeline of clinical candidates against chronic HCV and submit two additional IND applications during early 2011.
|
|
Read more...
|
|
